Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shigehiro Katayama reports administrative support, article publishing charges, statistical analysis, and writing assistance were provided by Bayer AG. He also reports lecture fees from Bayer. Stefan D Anker declares grants and personal fees from Abbott Vascular and Vifor Pharma, and personal fees for consultancies, trial committee work, and/or lectures from Actimed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BioVentrix, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Edwards, Faraday, Impulse Dynamics, Janssen, Novartis, Occlutech, Pfizer, Respicardia, Servier, Vectorious, and V-Wave. He is named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 and DE 102007022367), but he does not benefit personally from the related issued patents. Dalong Zhu has no competing interests to declare. SungGyun Kim reports research support from AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, Tricida, Alpine, Vera Therapeutics, Chinook/Novartis, Otsuka Pharmaceutical, and Vifor International. Ming-Ju Wu has no competing interests to declare. Daiji Kawanami reports consulting/lecture fees from Bayer Yakuhin Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Sanofi K.K., and Sumitomo Pharma Co., Ltd.; and grants from Bayer Yakuhin Ltd., Nippon Boehringer Ingelheim Co., Ltd., Nipro Corporation, and Sumitomo Pharma Co., Ltd. Peter Rossing reports personal fees from Bayer, during the conduct of the study; research support and personal fees from AstraZeneca and Novo Nordisk; and personal fees from Astellas, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, Sanofi, and Vifor. All fees are given to Steno Diabetes Center Copenhagen. He reports an equity interest in Novo Nordisk. Luis Miguel Ruilope reports consultant fees from Bayer. Christiane Ahlers, Meike Brinker, Amaninder Mann, Yunjing Tian, and Satoshi Yamashita are full-time employees of Bayer. Bertram Pitt reports consultant fees for AstraZeneca, Bayer, Boehringer Ingelheim, BrainStorm Medical, Cereno Scientific, G3 Pharmaceuticals, KBP Biosciences, PhaseBio, Proton Intelligence, Sanofi/Lexicon, Sarfez, scPharmaceuticals, SQ Innovation, Tricida, and Vifor Pharma/Relypsa; he has stock options for BrainStorm Medical, Cereno Scientific, G3 Pharmaceuticals, KBP Biosciences, Proton Intelligence, Sarfez, scPharmaceuticals, SQ Innovation, Tricida, and Vifor Pharma/Relypsa; he also holds a patent for site-specific delivery of eplerenone to the myocardium (US patent #9931412) and a provisional patent for histone acetylation-modulating agents for the treatment and prevention of organ injury (provisional patent US 63/045,784).
PubMed
